

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/572,349 Confirmation No.: 7557
Applicant: Asa Rosenquist, et al
Filed: January 2, 2007
TC/A.U.: 1654
Examiner: Julie Ha
Docket No.: 140309-3
Customer No.: 35684
For: Hcv ns-3 Serine Protease Inhibitors

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sirs:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the references listed on attached form PTO/SB/08a be considered by the Examiner and made of record. Copies of cited foreign patents are enclosed for the Examiner's convenience.


In accordance with 37 C.F.R. § 1.97(g) and (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, as an admission that the information cited herein is, or is considered to be, material to patentability, or that no other possible material information as defined in 37 C.F.R. § 1.56 exists.

Pursuant to 37 C.F.R. § 1.97(c), this Information Disclosure Statement is being submitted more than three months from the U.S. filing date, after the mailing date of the first Office Action on the merits, and before the mailing date of any of a final action under 37 CFR § 1.113, a notice of allowance under 37 CFR § 1.311, or an action that otherwise closes prosecution in the application, and is accompanied by the fee set forth in 37 C.F.R. § 1.17(p). Accordingly, the undersigned hereby authorizes the Commissioner of Patents to charge the necessary fee under 37

C.F.R. § 1.17(p) of \$180.00 to Deposit Account 12-2136, as well as any additional fees which may be due in connection with the filing of this paper.

Respectfully submitted,

Dated: May 22, 2009



Mehdi Ganjeizadeh
Registration No. 47585
Butzel Long
350 S. Main Street, Ste. 300
Ann Arbor, MI 48104
Tel. (734) 302-1029
Fax (734) 995-1777